Table 2.
Characteristics of Eligible Systematic Reviews
| Study | Aim | Search Strategy | Population | Intervention | Comparator | Outcomes | Included Studies |
|---|---|---|---|---|---|---|---|
| Health Quality Ontario24 | To assess the effect of GeneSight test compared to TAU | Timeline: Until February 2016 Databases: >2 Search terms: Provided Flow diagram: Available Limits: English only Test: GeneSight |
Depression, GAD, psychiatric patients (n=13,377) |
PGX-guided treatment with GeneSight | Unguided treatment | Primary outcomes: Prevention of suicide, remission, response, depression score, quality of life, efficacy Secondary outcomes: Impact on therapeutic decisions, patient and clinician satisfaction |
2 Non-randomized open-label studies 1 RCT 1 propensity score cohort |
| Bousman et al23 | To examine the remission rates of 2nd generation PGX-guided treatment in MDD patients | Timeline: Until May 2018 Databases: >2 Search terms: Provided Limits: English only Flow diagram: Available Test: Not specified |
Adults with but not limited to severe or uncontrolled depression (n=1737) |
PGX-guided treatment | Unguided treatment | Remission | 5 RCTs: 2 GeneSight, 1 Neuropharmagen, 1 CNSDose, 1 NeuroIDgenetix |
| Fabbri et al25 | To provide an update on the currently available PGx tests for predicting treatment outcomes of drugs for depression with quality evaluation for each available study | Timeline: Until January 2018 Databases: >2 Search terms: Provided Limits: English only Flow diagram: Available Test: Not specified |
Not clearly defined, but patients with depression (n=not available) |
PGX-guided treatment | Unguided treatment | Safety and efficacy | 6 RCTs: GeneSight, CNSDose, Neuropharmagen, NeuroIDgenetix, Genelex, academic study based on FKBP5 SNPs 6 case–control non- RCTs: 3 GeneSight, Genecept, GeneLex, academic study based on ABCB1 SNPs 9 observational studies 2 AmpliChip, CNSDose GeneSight, Genecept, Genelex, HILOmet, Neuropharmagen, Pillcheck |
| Rosenblat et al26 | To determine the effect of PGX-guided treatment on response and remission rates in the acute treatment of MDD as compared to unguided treatment | Timeline: Until December 2017 Databases: 2 Search terms: Provided Limits: Human studies, English only Flow diagram: Available Test: Not specified |
Patients with MDD (n=not available) | PGX-guided treatment | Unguided treatment | Response and remission |
4 RCTs: GeneSight, CNSDOse, Neuropharmagen, NeuroIDgenetix 2 Unblinded, open-label cohort studies 2 GeneSight |
| Rosenblat et al27 | To determine the effect of PGX testing on clinical outcomes in MDD and assess its cost-effectiveness | Timeline: Until October 2015 Databases: 2 Search terms: Provided Limits: English only Flow diagram: Available Test: Not specified |
Patients with MDD (n=not available) | Guided treatment | Unguided treatment | Efficacy, cost effectiveness | 2 case–control non- RCTs: 2 GeneSight 2 RCTs: GeneSight, CNSDose 1 Observational: Genecept |
| Brown et al28 | To assess the clinical utility of the combinatorial test GeneSight in patients with MDD | Timeline: Not available. Database: 1 Search terms: Provided. Limits: N/A Flow diagram: Available Test: GeneSight |
Patients with MDD with prior medication failure (n=1556) | Guided treatment with GeneSight | Unguided treatment | Symptoms improvement, response, remission | 2 RCTs 2 Open- label trials 1 Pooled analysis |
Abbreviations: PGX, pharmacogenetic; TAU, treatment as usual; MDD, major depressive disorder; RCT, randomized controlled trial; GAD, generalized anxiety disorder.